Trastuzumab Deruxtecan Delivers Broad Activity Across HER2 Breast Cancer Subgroups
Prospective evidence now paints a fairly consistent picture for trastuzumab deruxtecan in advanced breast cancer: the antibody-drug conjugate produces substantial tumor shrinkage across HER2-defined groups, while pulmonary toxicity remains the safety issue that most closely constrains wider use. A systematic review and meta-analysis synthesized prospective monotherapy studies and randomized trials through 2 August 2026, then separated absolute response estimates from comparative efficacy to avoid blurring very different forms of evidence.
The pooled response signal was strong in both major HER2 strata. In HER2-positive disease, the objective response rate reached 67.8% across 1,423 patients, with wide between-study heterogeneity. In HER2-low disease, the pooled objective response rate was 49.9% across 804 patients, again with substantial variability. Those numbers matter because they suggest the drug is not just active in amplified HER2 disease, where biologic dependence is obvious, but also in tumors with lower receptor expression where the signal has often been harder to capture with older anti-HER2 strategies.
Comparative Efficacy Held Up in Randomized Trials
The randomized data were handled separately and tell a more disciplined story than pooled efficacy alone. Across DESTINY-Breast02, DESTINY-Breast03, DESTINY-Breast04, and DESTINY-Breast06, progression-free survival hazard ratios were 0.36, 0.30, 0.50, and 0.62, respectively. In practical terms, those estimates consistently favored trastuzumab deruxtecan over the comparison regimens used in each study, although the effect size varied by population and setting.
One sentence captures the clinical pattern plainly: disease control improved across every randomized setting included in the review.
Overall survival was also favorable, with hazard ratios ranging from 0.66 to 0.83, although the confidence interval crossed 1 in DESTINY-Breast06. That nuance is important. Progression-free survival appears more reproducible than mature survival benefit in some of the newer HER2-low settings, where crossover, subsequent therapies, and shorter follow-up can blur the final survival signal. The review therefore supports confidence in anti-tumor activity without overstating the certainty of long-term survival advantage in every subgroup.
HER2-Ultralow Findings Remain Exploratory
The HER2-ultralow subgroup is still too small to treat as settled evidence, but the early signal is difficult to ignore. In that exploratory cohort, the objective response rate was 61.8%, based on 47 responses among 76 patients, and the progression-free survival hazard ratio was 0.78 with a confidence interval spanning 1.00. Biologically, this is the most intriguing part of the analysis, because it suggests that extremely low HER2 expression may still be enough to permit payload delivery in at least some tumors, even if the certainty around comparative benefit remains limited.
This is not a group where practice should pivot on enthusiasm alone. The sample is small, the estimate is exploratory, and the comparative time-to-event result is not yet definitive. Still, the direction of effect supports continued study of the ultralow phenotype rather than dismissing it as therapeutically irrelevant.
Pulmonary Toxicity Stayed Present Across the Evidence Base
Safety remains the counterweight to the efficacy signal. Across the pooled monotherapy dataset at 5.4 mg/kg every 3 weeks, interstitial lung disease or pneumonitis occurred in 13.2% of patients. Grade 3 or higher events were uncommon, at 1.8%, but fatal interstitial lung disease still occurred in 1.1% of patients. Those are not trivial numbers for a drug that is otherwise reshaping the treatment sequence in advanced breast cancer.
The mechanism of concern is clinically familiar for this class. An effective cytotoxic payload linked to a targeted antibody can produce meaningful tumor killing, yet any off-target lung injury becomes especially consequential because the adverse event can progress rapidly and may not announce itself early. Pulmonary symptoms, imaging changes, and steroid responsiveness all become bedside issues rather than abstract safety endpoints.
A second short point deserves emphasis: lung toxicity remains the main reason that efficacy must be paired with vigilant monitoring.
What the Heterogeneity Means for Treatment Sequencing
The heterogeneity across pooled response estimates should not be read as a weakness of the review so much as a reflection of the populations being compared. HER2-positive, HER2-low, and HER2-ultralow disease are not interchangeable biologically, and prior treatment exposure, line of therapy, and comparator choice all shape how large the benefit appears in any one trial. The random-effects approach used here was appropriate because it acknowledges that variability rather than pretending every study measures the same clinical reality.
For oncologists, the practical implication is straightforward: trastuzumab deruxtecan now has enough cross-study consistency to support its place as a high-activity option across HER2 expression categories in advanced breast cancer. The comparative benefit is clearest where randomized evidence is most mature, especially in progression-free survival, while the survival story is still evolving in some of the later HER2-low studies. Even so, the overall direction favors use of the drug when patients are eligible and pulmonary risk can be actively managed.
The Evidence Still Leaves Several Questions Open
The review is strong on synthesis, but it also exposes the boundaries of the current literature. HER2-ultralow evidence remains exploratory. Survival benefit is not uniformly mature across all trial settings. And the pooled safety signal, especially interstitial lung disease, continues to demand caution in real-world practice, where baseline lung disease, prior therapies, and monitoring intensity can differ from trial conditions.
Future studies will need to answer whether the apparent activity in ultralow disease persists in larger cohorts, whether different treatment lines alter the balance of benefit and toxicity, and how best to identify patients most likely to derive durable control without disproportionate pulmonary harm. For now, the review leaves clinicians with a clear but imperfect message: the drug is active across HER2 expression subgroups, yet its use still depends on careful patient selection and close attention to lung toxicity.